The Next 5 minutes will change your life

Merck, advancing single-dose and oral coronavirus vaccines, could still make Warp Speed: Bloomberg

The U.S. government’s Operation Warp Speed has already inked COVID-19 vaccine research and manufacturing pacts with major vaccine players—excluding Merck & Co., that is. But the group’s description of an as-yet-unnamed participant matches Merck’s early-stage research, Bloomberg reports, indicating the drugmaker could still get in.  

Merck publicly entered COVID-19 vaccine research later than its peers through a buyout of the biotech Themis and a partnership with nonprofit research group IAVI. The company started phase 1/2 testing earlier this month with technology acquired in the Themis buy. The IAVI partnership uses the same platform as Merck’s Ebola vaccine, which won FDA approval late last year.

Merck’s vaccines are live attenuated candidates, meaning they use weakened viruses that replicate in the body to generate an immune response. Merck is testing a vaccine that could be given orally, which would “help lower the barrier to vaccination should it be effective,” Merck R&D chief Roger Perlmutter said on a July conference call. 

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

“In dealing with an aggressive, globally dispersed disease like COVID-19, we believe that it is wise to lower the barrier to vaccination as much as possible, for example, by launching a vaccine that is effective with just a single administration,” Perlmutter said. 

Those details match the description of a vaccine that Moncef Slaoui, head of Operation Warp Speed, highlighted as a potential participant during a Wednesday presentation, according to Bloomberg. Merck and the Department of Health and Human Services declined to comment to the news service. 

RELATED: Merck, via its Themis buy, to move first COVID-19 vaccine into clinical development in Q3 

Back in June, the New York Times reported that Merck was among a group of companies selected as Warp Speed finalists. The drugmaker has yet to enter a public deal with the group.

To help support early research, Merck struck a $38 million deal with the U.S. government’s Biomedical Advanced Research and Development Authority in May.

Operation Warp Speed agreements have been on a much larger scale than that, though, with each coming in at $1 billion or more. Warp Speed already has deals with Moderna, AstraZeneca, Novavax, Johnson & Johnson, Sanofi/GSK and Pfizer/BioNTech, which are using various vaccine technologies.

RELATED: Trailing Big Pharma peers, Merck inks deals to advance COVID-19 drugs, vaccines 

Meanwhile, leading companies are already in phase 3 testing and could secure emergency use authorizations in late 2020 or early 2021. Most of the late-stage candidates are two-dose regimens, but Johnson & Johnson just entered phase 3 with a one-dose vaccine. Pfizer has said it expects early efficacy data in late October for its two-dose regimen.

Source link

The nest 5 minutes will change your view of making money from home.

About doc

Check Also

Indiana reports 24 more coronavirus deaths, 2,765 new cases

(WNDU) – Indiana health officials are reporting 2,765 more coronavirus cases and 24 more deaths …